More articles from 1-Minute Consult

  • When should I give corticosteroids to my patient with Pneumocystis pneumonia?
    Simran Gupta, MD and Lisa M. Bebell, MD, MSc, FIDSA
    Cleveland Clinic Journal of Medicine April 2024, 91 (4) 217-219; DOI: https://doi.org/10.3949/ccjm.91a.23082

    Patients with HIV infection who are hypoxemic should receive corticosteroids. Evidence for patients without HIV infection is limited.

  • Microscopic colitis: What is it, and what are the treatment options?
    Katherine E. Westbrook, DO and Ari Garber, MD, EdD, MS, EdM
    Cleveland Clinic Journal of Medicine April 2024, 91 (4) 215-216; DOI: https://doi.org/10.3949/ccjm.91a.23057

    Budesonide, first-line therapy for this inflammatory disorder characterized by chronic diarrhea, improves symptoms and quality of life.

  • Is there a role for chronic suppressive therapy in herpes simplex virus infection?
    Sandhya R. Nagarakanti, MD, FIDSA and Ahmed M. Zikri, PharmD
    Cleveland Clinic Journal of Medicine March 2024, 91 (3) 151-153; DOI: https://doi.org/10.3949/ccjm.91a.23099

    Yes, in patients with recurrent oral and genital HSV-2 infection and oral HSV-1 infection.

  • Does my patient have testosterone deficiency?
    Andrew D. Shumaker, MD, Navid Leelani, DO, Bradley Roth, Prajit Khooblall, MD, Raevti Bole, MD, Scott D. Lundy, MD, PhD and Petar Bajic, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 93-95; DOI: https://doi.org/10.3949/ccjm.91a.23064

    Diagnosis of testosterone deficiency requires the presence of relevant signs or symptoms along with biochemical evidence.

  • What are the management considerations for venous thromboembolic events in patients with cirrhosis?
    Marie M. Plante, MD, BSN, RN, Emily B. Wolf, MD and Razvan M. Chirila, MD
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 86-88; DOI: https://doi.org/10.3949/ccjm.91a.23045

    The authors review the current evidence on venous thromboembolic event (VTE) risk prediction in patients with cirrhosis, as well as VTE prophylaxis and anticoagulant therapy.

  • When should we consider SGLT-2 inhibitors in patients with acute decompensated heart failure?
    Osamah Z. Badwan, MD, Lorenzo Braghieri, MD, Warren Skoza, MD, Ankit Agrawal, MD, Venu Menon, MD and W. H. Wilson Tang, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 47-51; DOI: https://doi.org/10.3949/ccjm.91a.23034

    Evidence from clinical trials supports starting these medications as early as possible in patients hospitalized with acute decompensated heart failure who do not have clear contraindications to them.

  • Should my patients take their blood pressure medications in the evening to enhance cardiovascular benefit?
    Elias Bassil, MD, George Thomas, MD, Jagmeet Dhingra, MD and Ali Mehdi, MD, MEd, FACP, FASN
    Cleveland Clinic Journal of Medicine December 2023, 90 (12) 725-727; DOI: https://doi.org/10.3949/ccjm.90a.23043

    The focus should be to achieve blood pressure control and facilitate adherence, regardless of the timing of the medications.

  • What is the role for terlipressin in hepatorenal syndrome?
    Stephanie N. Bass, PharmD, Aanchal Kapoor, MD and Christina C. Lindenmeyer, MD
    Cleveland Clinic Journal of Medicine November 2023, 90 (11) 664-667; DOI: https://doi.org/10.3949/ccjm.90a.23037

    The drug is recommended as a first-line treatment of hepatorenal syndrome-related acute kidney injury, but it is associated with respiratory failure, especially in the setting of albumin administration, and certain comorbidities may increase the risk.

  • Is the MTHFR gene mutation associated with thrombosis?
    Andrew Dhawan, MD, DPhil and Charis Eng, MD, PhD
    Cleveland Clinic Journal of Medicine November 2023, 90 (11) 661-663; DOI: https://doi.org/10.3949/ccjm.90a.23044

    Clinicians should educate patients with this common polymorphism about the lack of evidence for associated thrombotic risk, and instead focus on modifiable risk factors for thrombosis.

  • Should I start an SGLT-2 inhibitor in my patient with heart failure and chronic kidney disease?
    Richard Sekerak, MD, Johanna Ben-Ami Lerner, MD, Pooja Prasad, MD and Megha Prasad, MD
    Cleveland Clinic Journal of Medicine October 2023, 90 (10) 607-609; DOI: https://doi.org/10.3949/ccjm.90a.23004

    These conditions often co-exist and can have complex interactions. The progression of kidney disease increases the risk of major adverse cardiovascular events.

Pages